PERBANDINGAN BIAYA PEMERIKSAAN LABORATORIUM PADA PASIEN TUBERKULOSIS MULTIDRUG RESISTANCE (TB-MDR) DENGAN TUBERKULOSIS EXTENSIVE DRUG RESISTANCE (TB-XDR): STUDI PADA RUMAH SAKIT TERSIER DI  BANDUNG

Raja Iqbal Mulya Harahap; Juandika Juandika; Dety Mulyanti

doi:10.59581/diagnosa-widyakarya.v1i1.156

Authors

Raja Iqbal Mulya Harahap Universitas Padjadjaran
Juandika Juandika Universitas Padjadjaran
Dety Mulyanti Universitas Padjadjaran

DOI:

https://doi.org/10.59581/diagnosa-widyakarya.v1i1.156

Keywords:

MDR-TB, XDR-TB, laboratory examination costs

Abstract

Introduction. Tuberculosis (TB) is one of the oldest diseases known to attack humans, caused by the bacterium Mycobacterium tuberculosis. Multi-drug-resistant TB (MDR-TB) is a stage or condition in which Mycobacterium tuberculosis becomes minimally resistant to rifampicin administration and also insonicotinylhydrazine (INH). Extensive-drug-resistant TB (XDR-TB) is an MDR-TB with Mycobacterium tuberculosis immune characteristics against one of the fluoroquinolone class drugs and one of the second-line injection OAT (capreomycin, kanamycin, and amikacin). The aim of this study was to find out the description of variation in laboratory costs of MDR-TB/XDR patients on one treatment cycle.

Method. The inclusion criteria were patients who had been diagnosed with MDR-TB/XDR and performed laboratory tests. The design of this study was a cross-sectional retrospective analytics using medical records of MDR-TB/XDR patients in MDR division.

Results. There were 30 MDR-TB research subjects and 2 XDR-TB research subjects examined for laboratory examination. Comparison of laboratory mean of MDR-TB/XDR (p = 0,018).

Discussion. There was a significant difference in the total cost of MDR-TB/XDR laboratory examinations in one treatment cycle.

Conclusion. Laboratory examination of MDR-TB/XDR patients requires considerable cost, this is due to the side effects of OAT that require patient clinical monitoring.

References

Raviglione MC, O’Brien RJ. Tuberculosis. Dalam: Kasper DL, Fauci AS, editor. Harrison's Principle of Internal Medicine. Massachusets: Mc Gram Hill; 2015. hlm. 953-6.

Dirjen P2PL. Pedoman Nasional Pengendalian Tuberkulosis. Kesehatan D, editor. Jakarta. 2017.

Dirjen P2PL. Pedoman Nasional Pengendalian Tuberkulosis. Jakarta. 2014.

Indonesia PDP. Tuberkulosis: Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Jakarta 2018.

Hood JL, Scott MG. Physiology and Disorders of Water, Electrolyte, and Acid-Base Metabolism. Dalam: Burtiz CE, Burns DE, editor. Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics. St Louis: Elsevier; 2016. hlm. 1609-81.

Wasiu Olalekan Adibempe AOF, Sulaiman Adebayo Nassar. Effects of treatment on free radicals in patients with pulmonary tuberculosis in South Western Nigeria. African Health Sciences. 2015;15(4):December 2015.

Greger R. Functions of The Kidney, Fluid and Electrolite Balance. Dalam: Gregor R, Windhorst U, editor. Comprehensive Human Physiology. Berlin: Springer; 2016. hlm. 1469-90.

Kementrian Kesehatan RI. Pedoman Nasional Pengendalian Tuberkulosis. Jakarta 2014.

Waspadji, Sarwono. Buku Ajar Ilmu Penyakit Dalam. Jilid II, Jakarta: 2015. hlm 365-86.

WHO. Guidelines for the programmatic management of drug-resistant tuberculosis. In: Dept ST, editor. Geneva 2016.

WHO. Multidrug and extensively drugresistant TB (M/XDR-TB) 2014 Global report on surveillance and response. Geneva: WHO; 2010.

Sekiguchi J, Miyoshi-Akiyama T, Augustynowicz-Kopec E, Zwolska Z, Kirikae F, Toyota E, et al. Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2017;45(1):179-92.